90 articles · updated regularly
Retatrutide (GLP-3) Research & Information
The definitive resource on retatrutide — the next-generation triple agonist weight loss drug. Research-backed, regularly updated, and independent.
Featured
What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.
Updated February 2026
Retatrutide Side Effects: TRIUMPH-3 & TRIUMPH-4 Phase 3 Safety Data (2026)
Phase 3 safety data — incidence rates for nausea, GI side effects, and the dysesthesia signal across TRIUMPH-3, TRIUMPH-4, and TRANSCEND-T2D-1.
Updated May 2026
Retatrutide and Food Noise: How Triple Agonism Quiets Cravings
How retatrutide's three receptors each contribute a distinct mechanism to reducing food noise, and what the Phase 2 data shows.
Updated March 2026
Retatrutide essentials
See all →What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.
Updated February 2026
How Does Retatrutide Work? Mechanism of Action Explained
The world's first triple agonist explained — how GLP-1, GIP, and glucagon receptors work together to reduce appetite and increase energy expenditure.
Updated February 2026
Retatrutide Brand Name: What Will It Be Called?
Eli Lilly hasn't announced a brand name for retatrutide yet. Expect it close to FDA approval in 2027.
Updated February 2026
Retatrutide Half-Life and Pharmacokinetics
Retatrutide has a ~6-day half-life achieved through fatty acid albumin binding — comparable to semaglutide (~7 days) and tirzepatide (~5 days).
Updated February 2026
Andrew Huberman on Retatrutide: What He Said and What the Data Shows
Huberman called retatrutide 'the peptide that changes everything.' Here's what he said and what the data actually shows.
Updated February 2026
Microdosing Retatrutide & GLP-1 Drugs: What the Research Shows
Current evidence on sub-therapeutic dosing and dose-splitting of GLP-1 receptor agonists.
Updated February 2026
Drug comparisons
See all →
Retatrutide vs Tirzepatide (Zepbound): Triple Agonist vs Dual Agonist
Retatrutide produces 28.7% weight loss (triple agonist) vs tirzepatide's 22.5% (dual agonist). A head-to-head trial is underway.
Updated February 2026
Retatrutide vs Mounjaro vs Ozempic
How the three generations of weight loss drugs compare — single, dual, and triple agonists.
Updated February 2026
Tirzepatide vs Semaglutide: Complete Comparison (2026 Data)
Tirzepatide vs semaglutide with SURMOUNT-5 head-to-head data: -20.2% vs -13.7% weight loss. Full comparison of efficacy, side effects, and access.
Updated February 2026
Zepbound vs Wegovy: Which Weight Loss Drug Is Better?
Zepbound produced -20.2% vs Wegovy's -13.7% weight loss in the SURMOUNT-5 head-to-head trial. Full comparison of cost, side effects, and CV data.
Updated February 2026
Mounjaro vs Ozempic: Which Is Better for Weight Loss and Diabetes?
Mounjaro produced twice the weight loss of Ozempic in head-to-head trials. Practical comparison of cost, insurance, and prescribing differences.
Updated February 2026
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Cagrilintide vs retatrutide: triple agonist vs amylin + GLP-1 combo — 28.7% vs 22.7% weight loss, different receptors, and stacking considerations.
Updated February 2026
GLP-1 guide
See all →
Which GLP-1 Drug Is Best for Weight Loss? (2026 Guide)
Decision framework for choosing the best GLP-1 drug: by max weight loss, CV protection, oral option, diabetes control, or liver fat.
Updated February 2026
GLP-1 Drug Comparison Tool: Compare Weight Loss Drugs Side by Side
Interactive comparison tool for GLP-1 weight loss drugs. Select 2-3 drugs to compare mechanism, efficacy, cost, and status.
Updated February 2026
GLP-1 vs GLP-2 vs GLP-3: What's the Difference?
GLP-1 and GLP-2 are real hormones. "GLP-3" is not — it's slang for retatrutide. Here's what each term actually means.
Updated February 2026
Tirzepatide vs Semaglutide: Complete Comparison (2026 Data)
Tirzepatide vs semaglutide with SURMOUNT-5 head-to-head data: -20.2% vs -13.7% weight loss. Full comparison of efficacy, side effects, and access.
Updated February 2026
Ozempic vs Wegovy: Same Drug, Different Purpose
Ozempic and Wegovy both contain semaglutide. The difference: indication (diabetes vs weight loss), max dose (2.0 vs 2.4 mg), and insurance coverage.
Updated February 2026
Mounjaro vs Ozempic: Which Is Better for Weight Loss and Diabetes?
Mounjaro produced twice the weight loss of Ozempic in head-to-head trials. Practical comparison of cost, insurance, and prescribing differences.
Updated February 2026
Peptides for weight loss
See all →
Peptides for Weight Loss vs GLP-1 Drugs: What the Evidence Says
GLP-1 drugs have Phase 3 trials and FDA approval. Research peptides have failed trials and animal data. The full evidence comparison.
Updated March 2026
Are Peptides Legal in 2026? The FDA Reclassification Explained
RFK announced 14 banned peptides returning to legal compounding. What it means, which peptides, and how it affects weight loss drugs.
Updated March 2026
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Updated February 2026
Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment
Retatrutide produced 28.7% weight loss in Phase 3 trials. AOD-9604 failed its largest trial. Here's how they compare.
Updated March 2026
Safety & side effects
See all →Retatrutide Side Effects: TRIUMPH-3 & TRIUMPH-4 Phase 3 Safety Data (2026)
Phase 3 safety data — incidence rates for nausea, GI side effects, and the dysesthesia signal across TRIUMPH-3, TRIUMPH-4, and TRANSCEND-T2D-1.
Updated May 2026
Retatrutide and Food Noise: How Triple Agonism Quiets Cravings
How retatrutide's three receptors each contribute a distinct mechanism to reducing food noise, and what the Phase 2 data shows.
Updated March 2026
Does Retatrutide Cause Muscle Loss?
The first DXA body composition data for retatrutide, the glucagon muscle-sparing hypothesis, and evidence-based strategies to preserve lean mass.
Updated February 2026
Weight Loss Drugs and Hair Loss: What Retatrutide's 24% Weight Loss Means
More weight loss means more hair shedding. Retatrutide's 24% weight loss likely puts it at the top — here's the clinical data and what to do about it.
Updated March 2026
Retatrutide and Pregnancy: What Triple Agonism Means for Fertility and Safety
Three receptors, three pregnancy concerns. What GLP-1, GIP, and glucagon receptor research means for retatrutide and reproductive safety.
Updated March 2026
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Updated February 2026
Clinical data & FDA
See all →
Retatrutide Phase 3 Trials 2026: TRIUMPH & TRANSCEND-T2D Tracker
Living tracker of every retatrutide trial — TRIUMPH-1/3/4/5, TRANSCEND-T2D-1/2, and SYNERGY-OUTCOMES Phase 3 readouts.
Updated May 2026
Retatrutide FDA Approval Timeline 2026-2028: Filing & Status
TRANSCEND-T2D-1 and TRIUMPH-3 are in. Projected FDA filing 2026-27, approval 2027-28. Live timeline.
Updated May 2026
Retatrutide Results: Before and After — What the Data Actually Shows
No real before/after photos exist. Here's what the clinical trial data shows: 28.7% average weight loss at 68 weeks, month-by-month breakdown.
Updated February 2026
How to Sign Up for a Retatrutide Clinical Trial
The only way to access retatrutide in 2026 is through clinical trials. Here's how to find and enroll in a TRIUMPH trial.
Updated February 2026
Other weight loss drugs
See all →
What Is Cagrilintide? The Amylin Analog Behind CagriSema
Novo Nordisk's long-acting amylin analog — 11.5% weight loss as monotherapy, and the key ingredient in CagriSema.
Updated February 2026
What Is CagriSema? Novo Nordisk's Amylin + GLP-1 Weight Loss Combination
Novo Nordisk's amylin + GLP-1 combination — 20.4% weight loss in REDEFINE 1, NDA filed December 2025.
Updated February 2026
What Is Foundayo (Orforglipron)? Lilly's FDA-Approved Oral GLP-1 Weight Loss Pill
Eli Lilly's FDA-approved oral GLP-1 pill — 12.4% weight loss, no injections, no fasting. Starting at $149/month.
Updated April 2026
What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH
Boehringer Ingelheim's dual GLP-1/glucagon agonist — 18.7% weight loss in Phase 2, 83% MASH resolution, Phase 3 ongoing.
Updated February 2026
What Is Mazdutide (Xinermei)? The First GLP-1/Glucagon Drug Approved in China
The first GLP-1/glucagon dual agonist approved anywhere — how it works, what the trials show, and why it matters for the obesity drug landscape.
Updated February 2026
What Is Amycretin? Novo Nordisk's Oral GLP-1/Amylin Weight Loss Drug
Novo Nordisk's first-in-class GLP-1/amylin dual agonist — 13.1% weight loss as a daily pill in 12 weeks, 22% as a weekly injection in 36 weeks.
Updated March 2026
Fact-checking viral videos
See all →
Coach Gary Miller on Retatrutide: His Protocol vs What the Data Shows
Gary Miller's retatrutide protocol fact-checked against Phase 2 and Phase 3 clinical data.
Updated February 2026
Dr. Ashley Froese on Retatrutide: Why It's the "King" of Fat Loss Peptides, Fact-Checked
A physician's retatrutide explainer fact-checked — GIP futile calcium cycling, glucagon thermogenesis, muscle loss, allodynia, and dosing.
Updated April 2026
Adrian Crook Quit Retatrutide After 6 Months: What He Learned
A 6-month retatrutide diary with DEXA data, craving elimination, and a PPI interaction warning.
Updated February 2026
Dr. Alex Tatem on Retatrutide: A Physician's Breakdown Fact-Checked
A physician's retatrutide explainer fact-checked — mechanism, Phase 2 data, drug comparisons, and FDA timeline.
Updated February 2026
GLP-3 Wiki is an independent informational resource. We are not affiliated with Eli Lilly, Novo Nordisk, or any pharmaceutical company. Retatrutide is an investigational drug that has not been approved by the FDA. This site is not medical advice. Always consult a healthcare provider before making decisions about medication.